Search

everythinglearnresearchcommunity

for

Search:↓

A female user with alopecia is researching peptide usage, specifically ghk-cu, for hair loss. Other users shared mixed experiences with copper treatments, noting some success with topical application.

The user is considering using 0.5 mg dutasteride once every 5 or 7 days due to side effects from finasteride and is also looking into topical liposomal dutasteride and pyrilutamide to stop hair loss. The goal is to stop hair loss, not regrow hair.

A 28-year-old is experiencing hair loss despite using treatments like oral minoxidil, finasteride, and high-dose dutasteride (2.5 mg). They suspect lichen planus might be contributing to the issue and plan to continue treatment while monitoring progress.

A 40-year-old shared progress pictures showing results after 3.5 months of using dutasteride for hair loss. The conversation likely discusses this specific treatment and its effects on hair regrowth.

Amino acids like lysine, methionine, and cysteine may help with androgenetic alopecia when taken in high doses along with a DHT blocker. Users discuss combining these with treatments like Minoxidil, finasteride, and RU58841.

The conversation is about using PTD-DBM and valproic acid for hair loss. The user is inquiring about the dosage of these treatments, noting that valproic acid is used at a 7.5% solution.

The conversation discusses the mechanism of action of alfatradiol (17 alpha estradiol) in treating hair loss. It explores theories that it either inhibits 5 alpha reductase to prevent T->DHT conversion or aromatizes scalp T into 17-alpha-estradiol to save hair.

Kintor Pharma finished enrolling and dosing participants in a Phase I trial for a hair loss treatment called AR-PROTAC (GT20029). The effectiveness of another drug, pyrilutamide (KX-826), for hair loss will be clearer after a Phase 2 trial expected to complete in January 2023.

The user is unhappy with the results of their second hair transplant, feeling that grafts were wasted on an already transplanted hairline instead of increasing mid-scalp density. They regret stopping medications like Dutasteride, Minoxidil, and RU58841, which led to significant hair loss, and plan to restart them.

PP405 is discussed as a potential hair growth stimulant, possibly more effective than minoxidil, but not a cure for hair loss. There is skepticism about its ability to regrow "deadzones," and concerns about its impact on those with hair transplants.

The user is considering using Tacrolimus Solution and topical Dutasteride to avoid shedding caused by Minoxidil, which they fear may lead to facial side effects. They are also concerned about scalp sensitivity and are exploring different treatment bases to manage seborrheic dermatitis.

The user experienced persistent acne and skin issues with dutasteride, leading them to stop its use. They switched to finasteride, which caused mild acne and potential liver concerns, prompting consideration of alternative treatments like topical finasteride and GHK-Cu.

Liver problems may reduce the effectiveness of oral minoxidil due to impaired SULT1A1 enzyme activity, which is crucial for converting minoxidil to its active form. This reduction in enzyme function can significantly decrease the drug's effectiveness in promoting hair growth.

A 35-year-old transgender woman experienced hair regrowth with feminizing HRT, adding dutasteride and bicalutamide, and plans a hair transplant for further improvement. Estrogen also improved skin appearance, and the user advises against cisgender men using feminizing HRT for hair regrowth.

A person had a hair transplant using FUE with 4150 grafts after a previous FUT with 2000 grafts and is now using Dutasteride and oral Minoxidil. They are concerned about hair gaps on the side, questioning if they are a result of the transplant and if they are temporary.

The user has severe diffuse thinning on the scalp and is using finasteride, topical minoxidil, dermarolling, tretinoin, and Nizoral without satisfactory results. They are considering a hair transplant but are concerned about the cost and the number of grafts needed.

A user shared their 9-month progress using RU58841 at 2% daily for hair regrowth, initially starting at 5% but reducing the dose due to early signs of gynecomastia, which has since mostly resolved. They achieved their goal of regrowing hair at the temples and hairline.

The conversation discusses the potential for developing a biologic "DHT sponge" to neutralize DHT in the bloodstream as a treatment for hair loss, suggesting it could be more targeted and have fewer side effects than current treatments like finasteride and dutasteride. Concerns include the complexity, cost, and potential side effects of such a treatment, as well as skepticism about its feasibility and market interest.

The conclusion of the conversation is that the user has experienced significant hair regrowth using a combination of medications, including dutasteride, RU58841, and minoxidil. They have not experienced any noticeable side effects and are considering a hair transplant in the future.

RU58841 is discussed as a treatment that stops scalp itching when used with finasteride or dutasteride. The user is considering trying RU58841 due to persistent itching despite using the "big 3" treatments.

The potential of lowering prolactin levels to regrow hair, with a reference to Bayer's drug HMI 115 which has been indicated as having this effect. Treatments mentioned include Minoxidil and Finasteride, as well as RU58841.

Concerns about metal particles from dermapen or dermaroller needles potentially entering the skin and lymph nodes, similar to tattoo needles. Discussion includes the possibility of using Minoxidil, finasteride, and RU58841 for hair loss treatment.

A user reported positive hair growth using a regimen of oral finasteride, minoxidil, Dr. Pen, keto shampoo, and a Capillus 272 LLLT cap. Other users debated the effectiveness of the LLLT cap, with some attributing the success to the combined treatments rather than the cap alone.

A user is documenting their natural approach to treating a receding hairline using a dermastamp, essential oils (rosemary oil at 3% dilution with pumpkin seed oil), a multivitamin with vitamin D, and daily collagen shakes. They acknowledge the common recommendations of minoxidil and finasteride but prefer to test natural methods and share their results.

The conversation discusses new hair loss treatments like stem cell therapy, exosome treatments, and DHI, with mentions of GT20029, Amp303, and Plated PRP Serum as promising options. It also notes the use of dutasteride, topical finasteride, and minoxidil, but the focus is on non-hormonal innovations.

The user experienced noticeable hair regrowth using topical minoxidil and a dermaroller within a month. They are advised to consider DHT inhibition for lasting results.

The conversation is about a user who had a hair transplant with 2,850 grafts and switched from finasteride and topical minoxidil to oral minoxidil and dutasteride for better results. They are hopeful for full results in a year.

The conversation discusses hair loss treatments, focusing on Tsuji's hair cloning and Shiseido's RCH-01, with skepticism about their effectiveness on humans. It compares these to PRP, noting PRP's higher efficacy in studies.

The conversation discusses the ineffectiveness of dutasteride in halting hair loss for the user and explores the potential of PP405, which works through a different mechanism. Suggestions include considering a biopsy to determine the cause of hair loss and exploring other treatments like RU58841.

Lichen Planopilaris (LPP), a form of permanent hair loss, which can be mistaken for seborrheic dermatitis and is characterized by scalp itching, burning, redness, and dandruff. Treatment options discussed include steroidal creams, finasteride, minoxidil, and RU58841.